{
  "id": [
    "26512781"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "26512781"
  ],
  "pmcid": [
    "PMC4747370"
  ],
  "doi": [
    "10.18632/oncotarget.5886"
  ],
  "title": [
    "A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations."
  ],
  "authorString": [
    "Chen D, Huang X, Cai J, Guo S, Qian W, Wery JP, Li QX."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Chen D"
          ],
          "firstName": [
            "Dawei"
          ],
          "lastName": [
            "Chen"
          ],
          "initials": [
            "D"
          ],
          "affiliation": [
            "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
          ]
        },
        {
          "fullName": [
            "Huang X"
          ],
          "firstName": [
            "Xuesong"
          ],
          "lastName": [
            "Huang"
          ],
          "initials": [
            "X"
          ],
          "affiliation": [
            "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
          ]
        },
        {
          "fullName": [
            "Cai J"
          ],
          "firstName": [
            "Jie"
          ],
          "lastName": [
            "Cai"
          ],
          "initials": [
            "J"
          ],
          "affiliation": [
            "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
          ]
        },
        {
          "fullName": [
            "Guo S"
          ],
          "firstName": [
            "Sheng"
          ],
          "lastName": [
            "Guo"
          ],
          "initials": [
            "S"
          ],
          "affiliation": [
            "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
          ]
        },
        {
          "fullName": [
            "Qian W"
          ],
          "firstName": [
            "Wubin"
          ],
          "lastName": [
            "Qian"
          ],
          "initials": [
            "W"
          ],
          "affiliation": [
            "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
          ]
        },
        {
          "fullName": [
            "Wery JP"
          ],
          "firstName": [
            "Jean-Pierre"
          ],
          "lastName": [
            "Wery"
          ],
          "initials": [
            "JP"
          ],
          "affiliation": [
            "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
          ]
        },
        {
          "fullName": [
            "Li QX"
          ],
          "firstName": [
            "Qi-Xiang"
          ],
          "lastName": [
            "Li"
          ],
          "initials": [
            "QX"
          ],
          "affiliation": [
            "State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China."
          ]
        }
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "38"
      ],
      "volume": [
        "6"
      ],
      "journalIssueId": [
        "2352232"
      ],
      "dateOfPublication": [
        "2015 Dec"
      ],
      "monthOfPublication": [
        "12"
      ],
      "yearOfPublication": [
        "2015"
      ],
      "printPublicationDate": [
        "2015-12-01"
      ],
      "journal": [
        {
          "title": [
            "Oncotarget"
          ],
          "ISOAbbreviation": [
            "Oncotarget"
          ],
          "medlineAbbreviation": [
            "Oncotarget"
          ],
          "NLMid": [
            "101532965"
          ],
          "ESSN": [
            "1949-2553"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2015"
  ],
  "pageInfo": [
    "40815-40821"
  ],
  "abstractText": [
    "Cetuximab is a standard of care for treating EGFR-expressing metastatic colorectal carcinoma (mCRC) exclusive of those with KRAS mutations at codons 12/13. However, retrospective analysis has recently suggested that KRAS-G13D patients can still benefit, while only a fraction of KRAS wild-type patients can benefit, from the treatment. We set out to test this contradicting issue experimentally in an independent cohort of patient derived xenograft (PDX) diseases. We conducted a mouse clinical trial (MCT) enrolling a random cohort of 27 transcriptome sequenced CRC-PDXs to evaluate cetuximab activity. The treatment responses were analyzed against the KRAS 12/13 mutation alleles, as well as several other well-known oncogenic alleles. If the response is defined by >80% tumor growth inhibition, 8/27 PDXs (~30%) are responders versus 19/27 non-/partial responders (~70%). We found that indeed there are no significantly fewer KRAS-12/13-allele responders (4/8 or 50%) than non-/partial responders (7/19, or 37%). In particular, there are actually no fewer G13D responders (4/8, or 50%) than in non-/partial responders (2/19 or 10.5%) statistically. Furthermore, majority of the non-/partial responders tend to have certain activating oncogenic alleles (one or more of the following common ones: K/N-RAS-G12V/D, -A146T, -Q61H/R, BRAF-V600E, AKT1-L52R and PIK3CA-E545G/K). Our data on an independent cohort support the recent clinical observation, but against the current practiced patient stratification in the cetuximab CRC treatment. Meanwhile, our data seem to suggest that a set of the six-oncogenic alleles may be of better predictive value than the current practiced stratification, justifying a new prospective clinical investigation on an independent cohort for confirmation."
  ],
  "affiliation": [
    "Crown Bioscience, Inc., Santa Clara, CA 95054, USA."
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "Journal Article"
      ]
    }
  ],
  "meshHeadingList": [
    {
      "meshHeading": [
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Tumor Cells, Cultured"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Animals"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Humans"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Mice"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Colorectal Neoplasms"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DT"
                  ],
                  "qualifierName": [
                    "drug therapy"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "PA"
                  ],
                  "qualifierName": [
                    "pathology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Proto-Oncogene Proteins"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Antineoplastic Agents"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Retrospective Studies"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Xenograft Model Antitumor Assays"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Gene Expression Regulation, Neoplastic"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Drug Resistance, Neoplasm"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Mutation"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Alleles"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Proto-Oncogene Proteins p21(ras)"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "High-Throughput Nucleotide Sequencing"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "MT"
                  ],
                  "qualifierName": [
                    "methods"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Biomarkers, Tumor"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Cetuximab"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Biomarker",
        "Kras",
        "Patient Stratification",
        "Pdx",
        "Erbitux"
      ]
    }
  ],
  "chemicalList": [
    {
      "chemical": [
        {
          "name": [
            "Antineoplastic Agents"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Proto-Oncogene Proteins"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Proto-Oncogene Proteins p21(ras)"
          ],
          "registryNumber": [
            "EC 3.6.5.2"
          ]
        },
        {
          "name": [
            "KRAS protein, human"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "cetuximab"
          ],
          "registryNumber": [
            "PQX0D8J21J"
          ]
        },
        {
          "name": [
            "Biomarkers, Tumor"
          ],
          "registryNumber": [
            "0"
          ]
        }
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC4747370?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC4747370"
          ]
        },
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "http://dx.doi.org/10.18632/oncotarget.5886"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "Y"
  ],
  "citedByCount": [
    "3"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "Y"
  ],
  "dbCrossReferenceList": [
    {
      "dbName": [
        "UNIPROT"
      ]
    }
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "license": [
    "cc by"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCompletion": [
    "2016-09-22"
  ],
  "dateOfCreation": [
    "2015-12-17"
  ],
  "dateOfRevision": [
    "2016-03-25"
  ],
  "firstPublicationDate": [
    "2015-10-26"
  ]
}